{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=40", "query": { "intervention": "Dose", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 50427, "total_pages": 5043, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T11:57:02.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00526630", "title": "Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease", "Gait Impairment" ], "interventions": [ { "name": "Methylphenidate (MPD)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 23, "start_date": "2007-12", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2015-04-22", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526630" }, { "nct_id": "NCT01206530", "title": "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colon Cancer", "Metastasis", "Adenocarcinoma" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206530" }, { "nct_id": "NCT03410030", "title": "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma Resectable", "Pancreatic Ductal Adenocarcinoma", "Pancreas Metastases" ], "interventions": [ { "name": "High Dose Ascorbic Acid 25 g/m^2", "type": "DRUG" }, { "name": "Nanoparticle Paclitaxel protein bound 125mg/m^2", "type": "DRUG" }, { "name": "Cisplatin 25mg/m^2", "type": "DRUG" }, { "name": "Gemcitabine 1000mg/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 37.5 g/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 56.25 g/m^2", "type": "DRUG" }, { "name": "High Dose Ascorbic Acid 75 g/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-12-15", "completion_date": "2023-09-06", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410030" }, { "nct_id": "NCT01492465", "title": "Single Ascending Dose Trial in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "AMG 876", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2011-11", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 3, "location_summary": "Omaha, Nebraska • San Antonio, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492465" }, { "nct_id": "NCT02225665", "title": "Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "SB-728mR-T", "type": "GENETIC" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-08", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2021-03-19", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 5, "location_summary": "San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02225665" }, { "nct_id": "NCT04509700", "title": "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Malignancies" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "parsaclisib + itacitinib", "type": "DRUG" }, { "name": "parsaclisib + ruxolitinib", "type": "DRUG" }, { "name": "parsaclisib + ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2020-08-03", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04509700" }, { "nct_id": "NCT00000667", "title": "A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": null, "completion_date": "1993-07", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000667" }, { "nct_id": "NCT00004107", "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody MN-14", "type": "RADIATION" }, { "name": "yttrium Y 90 epratuzumab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 18, "start_date": "1998-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 4, "location_summary": "Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Paterson", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004107" }, { "nct_id": "NCT00773812", "title": "Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autistic Disorder", "Pervasive Developmental Disorder" ], "interventions": [ { "name": "mecamylamine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "4 Years to 12 Years" }, "enrollment_count": 20, "start_date": "2007-07", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00773812" }, { "nct_id": "NCT01647711", "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Dose escalation followed by treatment with MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-10-29T11:57:02.629Z", "location_count": 2, "location_summary": "Aurora, Colorado • Boston, Massachusetts", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01647711" } ] }